CRBU
Caribou Biosciences, Inc.
Healthcare — Biotechnology
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Price History
Fundamentals
| Market Cap | $174.56M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.26 |
| EPS (TTM) | $-1.42 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 1.90% |
| ROE | -83.46% |
| Debt/Equity | 26.41 |
| Recommendation | None |
| Analyst Target | $12.00 |
| Analysts | 7 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 47.7 |
| Beta | 2.33 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.54 |
| 52-Week Low | $1.34 |
| 50-Day Avg | $1.96 |
| 200-Day Avg | $1.93 |
| Avg Volume | $1.91M |
| Volume | $1.69M |
Performance Analysis
NEUTRALCRBU presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:04 UTC
Back to Screener Export Report